Posted by Michael Wonder on 19 Oct 2017
Payers need access to pre-approval drug information
19 October 2017 - Healthcare payment in the United States is shifting toward value—a transformation that will require new approaches to how manufacturers share information with payers, according to speakers at an October 18 session at the Academy of Managed Care Pharmacy 2017 Nexus in Dallas.
Fast-track regulatory mechanisms like the FDA’s Breakthrough Therapy Designation mean that drugs are coming to market faster. To assess the budgetary impacts of pending approvals, payers need more information about drugs, more quickly, panelists agreed.
“We need as much information as soon as possible,” said Soumi Saha, PharmD, JD, director of pharmacy & regulatory affairs, AMCP. “The problem is that drugs are coming to market before clinical trial data is even publicly available. We’re denying coverage.”
